Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01200082 · ClinicalTrials.gov registry record
Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases
A clinical trial, sponsored by University of Nebraska.
- Terminated
- Registry status
- 430
- Enrollment target
NCT01200082 is a clinical trial that was terminated before completion, run by University of Nebraska. The registered enrollment target is 430 participants.
The verdict
NCT01200082 was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- 430 participants
- Enrollment target
Study Summary
The investigators hypothesize that the extent of sulfation of toxic BAs and their urinary elimination can be used as a biomarker to predict the severity and prognosis of hepatobiliary diseases. The investigators rationale in this project is that the discovery of biomarkers specific to liver injury would provide the foundation for a specific and non-invasive tool to evaluate disease prognosis, determine patients with higher risk of developing end-stage liver diseases, and determine patients with higher risk of recurrence of hepatobiliary complications after liver transplant. Patients on the liver transplant list are continuously monitored during their hospitalization and are scheduled for follow-up visits for 12 months after their release post-surgery. Disease progression will be evaluated by monitoring MELD scores, survival, incidence of liver transplant, and incidence of complications related to hepatobiliary conditions such as fluid retention, GI bleeding, encephalopathy, and biliary stricture complications.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2011-11 |
| Est. Completion | 2022-09-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01200082
The ClinicalTrials.gov registry entry for NCT01200082 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01200082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01200082 about?
NCT01200082 is a clinical study titled "Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases". The investigators hypothesize that the extent of sulfation of toxic BAs and their urinary elimination can be used as a biomarker to predict the severity and prognosis of hepatobiliary diseases. The investigators rationale in this project is that the discovery of biomarkers specific to liver injury w...
What is the current status of trial NCT01200082?
This trial is currently terminated. The enrollment target is 430 participants. The study started on 2011-11. Estimated completion is 2022-09-02.
Who is sponsoring clinical trial NCT01200082?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.